ArticleMedical oncology (Northwood, London, England)2008
Chemosensitization effects of simultaneous suppression of MDR1 and XIAP in multidrug resistant glioma cells.
Article in Medical oncology (Northwood, London, England), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 2 citations in OpenAlex.
- miR-214-3p Regulates Multi-Drug Resistance and Apoptosis in Retinoblastoma Cells by Targeting ABCB1 and XIAP.OncoTargets and therapy · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We studied the mechanisms involved in the drug resistance of C6/ADR and compared the reversal effects of XIAP and MDR1 ASO used in combination and separately. Reverse transcription-PCR and Western blot were applied to detect the mRNA and protein levels, respectively. The results showed that XIAP and MDR1 ASO used separately could down-regulate the levels of XIAP and MDR1 in C6/ADR cells, respectively. XIAP and MDR1 ASO used in combination did not enhance the inhibition expression of XIAP and MDR1 of C6/ADR cells. The apoptosis of co-transfection group was significantly higher than XIAP ASO (P < 0.05). When used in combination the sensitivity of C6/ADR cells to ADR was increased significantly compared with XIAP or MDR1 ASO used separately (P < 0.05). The results indicated that both XIAP and MDR1 were involved in the drug resistance of C6/ADR cells. The sensitivity to ADR could be enhanced significantly when XIAP and MDR1 ASO used in combination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.